Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.

Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage. The candidate, which will be developed by Poolbeg as POLB 002, was developed at the University of Warwick and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock.

Press release (17 January 2022)

An international group of researchers have created a new health economic framework that supports decision makers and funders in understanding the resources required to achieve the World Health Organization’s (WHO) goal of eliminating sleeping sickness by 2030.

Press release (13 December 2021)